NZ757708A - Applications of spermine and its derivative in preparation of antitumor drug - Google Patents

Applications of spermine and its derivative in preparation of antitumor drug

Info

Publication number
NZ757708A
NZ757708A NZ757708A NZ75770818A NZ757708A NZ 757708 A NZ757708 A NZ 757708A NZ 757708 A NZ757708 A NZ 757708A NZ 75770818 A NZ75770818 A NZ 75770818A NZ 757708 A NZ757708 A NZ 757708A
Authority
NZ
New Zealand
Prior art keywords
spermine
preparation
derivative
antitumor drug
applications
Prior art date
Application number
NZ757708A
Inventor
Wei Zhu
Wuguang Pan
Original Assignee
Geneheal Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneheal Biotechnology Co Ltd filed Critical Geneheal Biotechnology Co Ltd
Publication of NZ757708A publication Critical patent/NZ757708A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/9015—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

An application of spermine or its pharmaceutically acceptable derivative in preparation of an SAICAR synthetase activity interference agent or inhibitor. An application of spermine or its pharmaceutically acceptable derivative in preparation of an antitumor drug.
NZ757708A 2017-04-20 2018-02-06 Applications of spermine and its derivative in preparation of antitumor drug NZ757708A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710261440 2017-04-20
PCT/CN2018/075427 WO2018192293A1 (en) 2017-04-20 2018-02-06 Applications of spermine and its derivative in preparation of antitumor drug

Publications (1)

Publication Number Publication Date
NZ757708A true NZ757708A (en) 2022-01-28

Family

ID=63856309

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ757708A NZ757708A (en) 2017-04-20 2018-02-06 Applications of spermine and its derivative in preparation of antitumor drug

Country Status (11)

Country Link
US (1) US11684593B2 (en)
EP (1) EP3613416B1 (en)
JP (1) JP6810814B2 (en)
KR (1) KR20190122242A (en)
CN (1) CN110494131B (en)
AU (1) AU2018253671B2 (en)
CA (1) CA3057206C (en)
NZ (1) NZ757708A (en)
SG (1) SG11201908662XA (en)
WO (1) WO2018192293A1 (en)
ZA (1) ZA201906237B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018059214A1 (en) 2016-09-29 2018-04-05 广州君赫生物科技有限公司 Compounds affecting saicar synthesis, and applications
JP6810814B2 (en) 2017-04-20 2021-01-06 広州君赫生物科技有限公司 Use of spermine and its derivatives in the preparation of antitumor agents
AU2018253689B2 (en) * 2017-04-20 2020-07-23 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivative
WO2020147471A1 (en) * 2019-01-17 2020-07-23 广州君赫生物科技有限公司 New use of aspartic acid
CN118055769A (en) * 2021-08-11 2024-05-17 剑桥企业有限公司 Application of polyamine in brain tumor treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305425C (en) 1986-12-02 1992-07-21 Raymond J. Bergeron Anti-neoplastic spermine derivative
US4952585A (en) * 1988-12-15 1990-08-28 Merrell Dow Pharmaceuticals Inc. Castanospermine esters in the inhibition of tumor metastasis
US5541230A (en) 1993-11-05 1996-07-30 Us Health Therapeutic polyamines
WO1997011691A1 (en) * 1995-09-29 1997-04-03 Children's Medical Center Corporation Treatment of human prostate cancer with spermine
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
WO1999051213A2 (en) 1998-04-03 1999-10-14 Theodore Toney Ilenchuk The use of polyamines in the treatment of dermatological symptoms
CA2318004A1 (en) 1999-09-15 2001-03-15 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
ES2187288B1 (en) 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda AMINAS AS ANTI-ALCOHOLISM AGENTS.
EP1492564A2 (en) 2001-10-31 2005-01-05 Université Libre de Bruxelles Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
ITMI20031570A1 (en) 2003-07-31 2005-02-01 Giuliani Spa COMPOSITION FOR DIETARY, PHARMACEUTICAL OR COSMETIC USE
CN101205555A (en) 2006-12-18 2008-06-25 中国疾病预防控制中心寄生虫病预防控制所 Schistosoma japonicum resistant medicine action target, medicine sifting method and lead compounds
CN101037423A (en) * 2007-04-16 2007-09-19 河南大学 High spermidine conjugates, preparation and application thereof
WO2009151569A2 (en) 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
AU2010284221B2 (en) 2009-08-18 2016-09-22 Casero, Robert A (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
WO2013003812A2 (en) 2011-06-29 2013-01-03 The Oregon State Board Of Higher Education On Behalf Of Portland State University Analyte detection using near-infrared fluorophores
FR2980709B1 (en) 2011-09-29 2013-10-25 Nutrialys Medical Nutrition Sa COMPOSITIONS CONTAINING SPERMINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
WO2014067038A1 (en) 2012-10-29 2014-05-08 广州百赫医疗信息科技有限公司 Target point, preparation and method for treating human adsl deficiency
CN104918611A (en) 2012-11-14 2015-09-16 百奥马克科技有限公司 Spermidine/spermine n1-acetyltransferase substrates as anti-cancer drug compounds
CA2900108A1 (en) 2013-01-30 2014-08-07 Biomark Technologies Inc. Spermidine/spermine n1-acetyltransferase antibodies as anti-cancer drug compounds
US20160369281A1 (en) 2015-06-16 2016-12-22 Geneheal Biotechnology Co., Ltd. Target point, preparation and method for treating human ADSL deficiency
CN106399380A (en) 2016-09-13 2017-02-15 上海云舜生物技术有限公司 Compound containing anti-PD (Program Death)-1 gene and poly-spermidine and application of compound to treatment of tumors
US10709676B2 (en) 2016-09-29 2020-07-14 Geneheal Biotechnology Co., Ltd. Applications of spermine and derivatives thereof
WO2018059214A1 (en) 2016-09-29 2018-04-05 广州君赫生物科技有限公司 Compounds affecting saicar synthesis, and applications
JP6810814B2 (en) 2017-04-20 2021-01-06 広州君赫生物科技有限公司 Use of spermine and its derivatives in the preparation of antitumor agents

Also Published As

Publication number Publication date
AU2018253671A1 (en) 2019-10-10
KR20190122242A (en) 2019-10-29
SG11201908662XA (en) 2019-11-28
CA3057206C (en) 2022-11-01
CN110494131A (en) 2019-11-22
EP3613416A1 (en) 2020-02-26
CN110494131B (en) 2022-11-08
ZA201906237B (en) 2021-04-28
WO2018192293A1 (en) 2018-10-25
US11684593B2 (en) 2023-06-27
US20200330402A1 (en) 2020-10-22
JP6810814B2 (en) 2021-01-06
CA3057206A1 (en) 2018-10-25
AU2018253671B2 (en) 2020-08-20
JP2020511500A (en) 2020-04-16
EP3613416A4 (en) 2020-10-21
EP3613416B1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
NZ757708A (en) Applications of spermine and its derivative in preparation of antitumor drug
PH12020550622A1 (en) Kras g12c inhibitors
EP3820279A4 (en) Temporally and spatially targeted dynamic nitrogen delivery by remodeled microbes
MX2019012534A (en) Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent.
EP3658557A4 (en) Tyk2 inhibitors and uses thereof
MX2018008190A (en) Systems and methods for long term transdermal administration.
EP3700902B8 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
MX2019012434A (en) Apoptosis-inducing agents.
EP3668504A4 (en) Macrocyclic mcl-1 inhibitors and methods of use
EP3681479A4 (en) Method of administration and treatment
EP3652184A4 (en) Macrocyclic mcl-1 inhibitors and methods of use
EP3668502A4 (en) Macrocyclic mcl-1 inhibitors and methods of use
EP3873442A4 (en) Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
EP3592731A4 (en) Inhibitors of malt1 and uses thereof
EP3694832A4 (en) Extended release pharmaceutical formulation and methods of treatment
EP3632437A4 (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
EP3498280A4 (en) Administration and dosage of therapeutic agent for endometriosis
SG11202112129SA (en) Drug conjugates and methods of using same
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
EP3563851A4 (en) Antitumor agent and bromodomain inhibitor
EP3706744A4 (en) Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
EP3517537A4 (en) Deuterated derivative of l-tetrahydropalmatine and medical use thereof
EP3675864A4 (en) First-in-class of shmt2 and mthfd2 inhibitors as antitumor agents
EP3612185A4 (en) Pharmaceutical compositions comprising poh derivatives and methods of use
IL277409A (en) Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 FEB 2024 BY CPA GLOBAL

Effective date: 20230112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 FEB 2025 BY CPA GLOBAL

Effective date: 20240104